Olaf Hardt

The paper develops a high-throughput TCR discovery assay to identify antigen-specific T cells, finding over 90 SARS-CoV-2-specific TCR clonotypes in one donor and nearly 1,000 in five donors.

This study shows that combinatorial adapter targeting in AdCAR T cells can selectively kill pancreatic cancer cells while avoiding off-tumor toxicity, but activation thresholds vary between donors.

This study develops functional CLA-targeting CAR approaches for pancreatic ductal adenocarcinoma by addressing limitations in CAR activity through genetic modification, affinity optimization, and novel AdCAR strategies.